In a move to improve obesity care in India, Emcure Pharmaceuticals has announced a significant price reduction of its weight management drug, Poviztra. This move, effective April 3, 2026, reduces the cost by up to 55%, making Semaglutide therapy more accessible and affordable for patients nationally.
Proviztra contains semaglutide, which is used in the treatment of type 2 diabetes and chronic weight management. It works by mimicking the GLP-1 hormone, helping to lower blood sugar levels, reduce appetite, and delay gastric emptying. The starting dose of Poviztra, previously available at a price of Rs. 8790, is now available at a price of Rs. 3999 per month (inclusive of taxes).
This price revision aims to enhance patient access to long-term therapy and improve treatment adherence. This move not only reflects patient affordability and accessibility, but it also sheds light on the growing concern surrounding the obesity epidemic in India. Obesity has become a major public health concern in recent years, driven by changing lifestyles, dietary patterns, and reduced physical activity.
Access to affordable therapy for obesity management is vital, as high treatment costs often prevent patients from receiving proper care, leading to worsening health outcomes and related disorders.
In conclusion, healthcare companies should prioritise making medications more accessible and affordable, ensuring that all patients receive essential treatment without facing financial barriers.
Reference:
The Economic Times. (2026). Emcure slashes prices of weight management drug Poviztra by up to 55%. Available from:
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/emcure-slashes-prices-of-weight-management-drug-poviztra-by-up-to-55/articleshow/129981567.cms?from=mdr
MBH/PS